PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
The company owns issued use-patents giving the right to treat diabetes and obesity with TRPV1 antagonists.
Our safe clinical development candidate, XEN-D0501, has entered the first clinical trials in type-2 diabetic patients in 2017.
Uppstickaren som vill ta plats i läkemedelsindustrin.
An interview with CEO Dorte X. Gram published in ‘DI Almedalen, Distributed with Dagens Industri, Sweden.
Read the article in Swedish here